The role of pharmacogenetics in the area of cancer chemotherapy and the development of malignancy has not been well defined. Only four chemotherapeutic agents have been evaluated for toxicity or clinical response based on genetic differences in metabolism. These include 5-fluorouracil, 6-mercaptopurine, amonafide, and cyclophosphamide. Severe toxicity of 5-fluorouracil and amonafide due to individual differ-ences in drug metabolism has been reported in the literature. Tumor response in leukemic children may be associated with genetic differences in metabolism of 6-mercaptorpurine. The development of malignancy HE ROLE OF pharmacogenetics in the T area of cancer chemotherapy is currently in its infancy. Polymorphic alterations in spe-cific enzymes have been implicated in causin
To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.